Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
Zhongmei Lin's dataset compares survival and progression patterns for patients with locally advanced unresectable esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy (CRT) alone versus CRT combined with immune checkpoint inhibitors (ICIs). The data covers 67 patients in the CRT+ICIs group and 415 historical controls from Fujian Cancer Hospital between August 2019 and August 2024, analyzed after 1:3 propensity score matching. It includes metrics such as median overall survival (31.1 vs. 18.6 months), progression-free survival, and adverse event rates.
The primary data file is a 254.0 KB PDF, which is a small file likely containing summary tables and analysis rather than a raw, machine-readable dataset.